Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM88IBE)

Drug Name

APD418 Drug Info

Synonyms

Vemtoberant; 2169905-68-2; vemtoberant [INN]; 4IJ6WR3BW8; APD418; SCHEMBL19707104; APD-418; BDBM484072; EX-A7995; US10927123, Compound 310; HY-148804; CS-0641193; 1-ethyl-3-((R)-3-((S)-2- hydroxy-3-(3- (methylsulfonyl)phenoxy) propylamino)-1-oxa- 8-azaspiro[4.5]decan-8- ylsulfonyl)quinolin- 4(1H)-one; 1-ethyl-3-[(3R)-3-({(2S)-2-hydroxy-3-[3- (methanesulfonyl)phenoxy]propyl}amino)-1-oxa-8- azaspiro[4.5]decane-8-sulfonyl]quinolin-4(1H)-one

Indication

Disease Entry	ICD 11	Status	REF
Heart failure with reduced ejection fraction	BD11.2	Phase 2	[1]

Cross-matching ID

PubChem CID: 132225057
TTD Drug ID: DM88IBE

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-3 (ADRB3)	TTMXGCW	ADRB3_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Adrenergic receptor beta-3 (ADRB3)	DTT	ADRB3	2.392	2.655	2.278	1.982

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Heart failure with reduced ejection fraction

ICD Disease Classification

BD11.2

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Adrenergic receptor beta-3 (ADRB3)	DTT	ADRB3	7.81E-01	0.02	0.16

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT05139615) A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of APD418 in Subjects With Heart Failure With Reduced Ejection Fraction. U.S.National Institutes of Health.
2	Intravenous Infusion of the beta(3)-Adrenergic Receptor Antagonist APD418 Improves Left Ventricular Systolic Function in Dogs With Systolic Heart Failure. J Card Fail. 2021 Feb;27(2):242-252.